<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081077</url>
  </required_header>
  <id_info>
    <org_study_id>PRACTECAL-PKPD</org_study_id>
    <nct_id>NCT04081077</nct_id>
  </id_info>
  <brief_title>PRACTECAL-PKPD Sub Study</brief_title>
  <acronym>PRACTECAL-PKPD</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medecins Sans Frontieres, Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>eResearch Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Republic of Uzbekistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Public Health, Republic of Belarus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>THINK TB &amp; HIV Investigative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wits Health Consortium (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minsk Republican Research and Practical Centre for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medecins Sans Frontieres, Netherlands</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating&#xD;
      the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the&#xD;
      TB-PRACTECAL trial investigational regimens and their respective treatment outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRACTECAL-PKPD is a sub-study of the main TB-PRACTECAL phase II-III trial for the treatment&#xD;
      of biologically confirmed pulmonary multi drug or extensively drug-resistant TB (M/XDR-TB).&#xD;
      TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating 6&#xD;
      months, exclusively oral regimens containing bedaquiline (B), pretomanid (Pa), linezolid&#xD;
      (Lzd) +/- moxifloxacin (Mfx) or clofazimine (Cfz) for the treatment of microbiologically&#xD;
      confirmed pulmonary M/XDR-TB.&#xD;
&#xD;
      Primary objective Measure the plasma concentrations of pretomanid, linezolid, bedaquiline,&#xD;
      clofazimine and moxifloxacin in a sub-set of patients in the TB-PRACTECAL trial and using&#xD;
      population pharmacokinetic (PK) models, estimate the population exposure metrics (minimum&#xD;
      plasma concentration (Cmin), mean plasma concentration (Cmean), maximum plasma concentration&#xD;
      (Cmax), plasma concentration versus time curve (AUC)) for the individual drugs in the&#xD;
      TB-PRACTECAL trial.&#xD;
&#xD;
      Secondary objectives Develop a population pharmacodynamic model to explore the relationship&#xD;
      between drug exposure, baseline minimum inhibitory concentrations and both&#xD;
      mycobacteriological and clinical treatment success Develop a population pharmacodynamics&#xD;
      model and identify PK parameters that are associated with treatment emergent toxicity Explore&#xD;
      covariates specific to the regimens and study population Use results of above objectives to&#xD;
      develop a hypothesis on the optimal dosing of linezolid and clofazimine Explore the&#xD;
      pharmacogenomic factors associated with efficacy and toxicity of the investigational drugs&#xD;
      Analyse adherence/exposure to the investigational regimen(s) by analysing anti-TB drug levels&#xD;
      in small hair samples Assess the potential of using hair drug levels to develop safety and&#xD;
      efficacy pharmacodynamic models Conduct clinical validation of a dried blood quantification&#xD;
      method using volumetric absorptive microsampling.&#xD;
&#xD;
      Procedures:&#xD;
&#xD;
      4 ml (vacutainer tube, lithium heparin) of blood will be collected from the hand, forearm or&#xD;
      antecubital vein at each sampling occasion and moment for the PK. The sampling occasions are&#xD;
      on Day 1, Weeks 8, 12, 16, 20, 24, 32 and 72. On Day 1, blood will be collected just before&#xD;
      drugs intake, then 2 and 23 hours after drugs intake. On week 8, blood will be collected just&#xD;
      before drugs intake, then 6.5 and 23 hours post dose. At weeks 12, 16, 20 and 24 the blood&#xD;
      will be collected within 30 minutes before taking the dose. Samples from week 32 and 72 will&#xD;
      be collected whenever feasible after the patients have completed their treatment so blood&#xD;
      collection is not relative to drug intake on that occasion. These have been included to&#xD;
      capture the elimination phases of the drugs which have long terminal half-lives.&#xD;
&#xD;
      A subgroup of patients will also participate to the clinical validation study of a dried&#xD;
      blood quantification method using volumetric absorptive microsampling. 2ml of blood and a&#xD;
      drop of blood from the finger tips will be collected at the following sampling occasions: day&#xD;
      1, week 8, 12 and 16.&#xD;
&#xD;
      In the small hair study, a small thatch of hair will be cut as close as possible to the scalp&#xD;
      from the occiput at weeks 8, 16, 24, 32 and 72.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUC</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: T1/2</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the elimnation half life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Tmax</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the time present at maximum plamsa concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>72 weeks</time_frame>
    <description>Number of patients with serious adverse events (SAE), adverse events of special interest (AESI) and other AEs with their respective severity grading.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics: Culture Conversion 24 weeks post treatment [Efficacy]</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of patients with culture conversion in liquid media at 24 weeks post randomisation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Multi-drug Resistant Tuberculosis</condition>
  <condition>Extensively Drug-Resistant Tuberculosis</condition>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <other_name>Sirturo</other_name>
    <other_name>R207910</other_name>
    <other_name>TMC207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretomanid</intervention_name>
    <description>Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <other_name>PA-824</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <other_name>Avelox, BAY 12-8039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.</description>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <other_name>Lamprene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main study inclusion criteria*:&#xD;
&#xD;
        Patients eligible for inclusion in the trial must fulfil all of the following criteria:&#xD;
&#xD;
          -  Male or female subjects aged 15 years of age or above, regardless of HIV status;&#xD;
&#xD;
          -  Microbiological test (molecular or phenotypic) confirming presence of M. tuberculosis;&#xD;
&#xD;
          -  Resistant to at least rifampicin by either molecular or phenotypic drug susceptibility&#xD;
             test;&#xD;
&#xD;
          -  Completed informed consent form (ICF);&#xD;
&#xD;
        Main study exclusion criteria:&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to any of the study drugs;&#xD;
&#xD;
          -  Pregnant or breast-feeding; or unwilling to use appropriate contraceptive measures&#xD;
&#xD;
          -  Liver enzymes &gt;3 times the upper limit of normal;&#xD;
&#xD;
          -  Any condition (social or medical) which, in the opinion of the investigator, would&#xD;
             make study participation unsafe;&#xD;
&#xD;
          -  Taking any medications contraindicated with the medicines in the trial; QTcF &gt; 450ms;&#xD;
&#xD;
          -  One or more risk factors for QT prolongation (excluding age and gender) or other&#xD;
             uncorrected risk factors for TdP;&#xD;
&#xD;
          -  History of cardiac disease, syncopal episodes, symptomatic or asymptomatic arrhythmias&#xD;
             (with the exception of sinus arrhythmia);&#xD;
&#xD;
          -  Any baseline biochemical laboratory value consistent with Grade 4 toxicity.&#xD;
&#xD;
          -  Moribund&#xD;
&#xD;
          -  Known resistance to bedaquiline, pretomanid, delamanid or linezolid.&#xD;
&#xD;
          -  Prior use of bedaquiline and/or pretomanid and/or linezolid and/or delamanid for one&#xD;
             or more months.&#xD;
&#xD;
          -  Patients not eligible to start a new course of MDR-TB/XDR-TB treatment according to&#xD;
             local protocol, including but not limited to:&#xD;
&#xD;
               -  currently on MDR-TB treatment for more than 2 weeks (and not failing)&#xD;
&#xD;
               -  unstable address&#xD;
&#xD;
               -  loss to follow-up in previous treatment with no change in circumstance and&#xD;
                  motivation.&#xD;
&#xD;
          -  Tuberculous meningoencephalitis, brain abscesses, osteomyelitis or arthritis.&#xD;
&#xD;
             *PKPD inclusion/exclusion:&#xD;
&#xD;
          -  Adult patients (aged 18 years or above) recruited into the investigational arms of the&#xD;
             TB-PRACTECAL trial in the approved sites.&#xD;
&#xD;
          -  Willing to sign the sub-study informed consent form after agreeing to the additional&#xD;
             blood draws.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bern Nyang'wa, MB BS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medecins Sans Frontieres, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen Jospeh Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doris Goodwin Hospital</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THINK Clinical Trial Unit, Hillcrest</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>3650</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King DinuZulu Hospital</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmcogenomics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Bedaquiline</keyword>
  <keyword>Pretomanid</keyword>
  <keyword>Linezolid</keyword>
  <keyword>Clofazimine</keyword>
  <keyword>Moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
    <mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

